Mallinckrodt (MNK) wins IPR decisions on INOMax blood-vessel drug - Bloomberg

September 16, 2016 9:56 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Mallinckrodt (NYSE: MNK) wins IPR decisions on INOMax blood-vessel drug, according to Bloomberg.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Litigation, Trader Talk

Add Your Comment